This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
https://awmsg.nhs.wales/
.
Home
|
About us
|
Contact us
About AWMSG
All Wales Medicines Strategy Group (AWMSG)
New Medicines Group (NMG)
All Wales Prescribing Advisory Group (AWPAG)
Meetings
Appraisals
Appraisal information
Patients/carers/patient organisations
Healthcare professionals
Pharmaceutical industry
Search and reports
Search and browse
Reports
Medicines management
About
Forthcoming work programme
National prescribing indicators
Clinical effectiveness prescribing programme
Appraisal monitoring
In-patient medication administration record
Patient information leaflets
Library
recombinant L-asparaginase (Spectrila®)
Reference No. 2968
Publication date:
03/05/2016
Appraisal information
recombinant L-asparaginase (Spectrila®) 10 000 U powder for concentrate for solution for infusion
Company:
medac GmbH
BNF category:
Malignant disease and immunosupression
NMG meeting date:
Not scheduled
AWMSG meeting date:
Not scheduled
Submission Type:
Nonsubmission
Status:
Not endorsed
Advice No:
Not available
Ratification by Welsh Government:
29/04/2016
Current Progress
Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government
AWMSG advice
In the absence of a submission from the holder of the marketing authorisation, asparaginase (Spectrila®) cannot be endorsed for use within NHS Wales as a component of antineoplastic combination therapy for the treatment of acute lymphoblastic leukaemia in paediatric patients from birth to 18 years and adult patients.
Statement of Advice (SOA)
Download
asparaginase (Spectrila) 2968 SOA
